MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 620103 | Name: Doxorubicin-MVCP

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doxorubicin-MVCP, also known as MC-Val-Cit-PAB-Doxorubicin, is a Doxorubicin derivative with a MC-Val-Cit-PAB linker. Mc-Val-Cit-PAB is a cathepsin cleavable ADC peptide linker. Doxorubicin-MVCP can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Doxorubicin-MVCP is a useful agent to make Doxorubicin-conjugate for drug delivery, nanodrug research.

Chemical Structure

Doxorubicin-MVCP
Doxorubicin-MVCP
CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 620103

Name: Doxorubicin-MVCP

CAS#: Unknown

Chemical Formula: C56H67N7O19

Exact Mass: 1141.4492

Molecular Weight: 1142.18

Elemental Analysis: C, 58.89; H, 5.91; N, 8.58; O, 26.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Doxorubicin-MVCP; MC-Val-Cit-PAB-Doxorubicin; MC-Val-Cit-PAB-Dox.
IUPAC/Chemical Name
4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamate
InChi Key
AYPRDRFYAQTVPD-GITVTGCLSA-N
InChi Code
InChI=1S/C56H67N7O19/c1-27(2)46(62-38(66)13-6-5-7-21-63-39(67)18-19-40(63)68)53(75)60-33(11-9-20-58-54(57)76)52(74)59-30-16-14-29(15-17-30)26-80-55(77)61-34-22-41(81-28(3)47(34)69)82-36-24-56(78,37(65)25-64)23-32-43(36)51(73)45-44(49(32)71)48(70)31-10-8-12-35(79-4)42(31)50(45)72/h8,10,12,14-19,27-28,33-34,36,41,46-47,64,69,71,73,78H,5-7,9,11,13,20-26H2,1-4H3,(H,59,74)(H,60,75)(H,61,77)(H,62,66)(H3,57,58,76)/t28-,33-,34-,36-,41-,46-,47+,56-/m0/s1
SMILES Code
O=C1C=CC(N1CCCCCC(N[C@@H](C(C)C)C(N[C@H](C(NC(C=C2)=CC=C2COC(N[C@@H](C[C@H](O[C@H]3C[C@@](C(CO)=O)(O)CC4=C(O)C(C(C5=CC=CC(OC)=C5C6=O)=O)=C6C(O)=C43)O7)[C@H](O)[C@@H]7C)=O)=O)CCCNC(N)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Please also see similar products: #610235: MC-Val-Cit-PAB (ADC peptide linker) #610234: MC-Val-Cit-PAB-PNP (ADC peptide linker)

Preparing Stock Solutions

The following data is based on the product molecular weight 1,142.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chung SW, Lee BS, Choi Ju, Kim SW, Kim IS, Kim SY, Byun Y. Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis. J Med Chem. 2015 Aug 27;58(16):6435-47. doi: 10.1021/acs.jmedchem.5b00420. Epub 2015 Aug 18. PubMed PMID: 26263187. 2: Lin W, Xie X, Deng J, Liu H, Chen Y, Fu X, Liu H, Yang Y. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery. J Drug Target. 2016 Feb;24(2):134-46. doi: 10.3109/1061186X.2015.1058802. Epub 2015 Jul 15. PubMed PMID: 26176270. 3: Yu Q, Wei Z, Shi J, Guan S, Du N, Shen T, Tang H, Jia B, Wang F, Gan Z. Polymer-Doxorubicin Conjugate Micelles Based on Poly(ethylene glycol) and Poly(N-(2-hydroxypropyl) methacrylamide): Effect of Negative Charge and Molecular Weight on Biodistribution and Blood Clearance. Biomacromolecules. 2015 Sep 14;16(9):2645-55. doi: 10.1021/acs.biomac.5b00460. Epub 2015 Aug 4. PubMed PMID: 26133354. 4: Mizusako H, Tagami T, Hattori K, Ozeki T. Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. J Pharm Sci. 2015 Sep;104(9):2934-40. doi: 10.1002/jps.24428. Epub 2015 May 4. PubMed PMID: 25940848. 5: Xu W, Ding J, Xiao C, Li L, Zhuang X, Chen X. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. Biomaterials. 2015 Jun;54:72-86. doi: 10.1016/j.biomaterials.2015.03.021. Epub 2015 Mar 30. PubMed PMID: 25907041. 6: Fan M, Yang D, Liang X, Ao J, Li Z, Wang H, Shi B. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Biomed Pharmacother. 2015 Mar;70:268-73. doi: 10.1016/j.biopha.2015.01.027. Epub 2015 Feb 7. PubMed PMID: 25776511. 7: Li J, Zhou Y, Li C, Wang D, Gao Y, Zhang C, Zhao L, Li Y, Liu Y, Li X. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy. Bioconjug Chem. 2015 Jan 21;26(1):110-9. doi: 10.1021/bc5004718. Epub 2014 Dec 29. PubMed PMID: 25506713. 8: Di Meo C, Cilurzo F, Licciardi M, Scialabba C, Sabia R, Paolino D, Capitani D, Fresta M, Giammona G, Villani C, Matricardi P. Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy. Pharm Res. 2015 May;32(5):1557-69. doi: 10.1007/s11095-014-1557-2. Epub 2014 Oct 31. PubMed PMID: 25366547. 9: Low SA, Yang J, Kopeček J. Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics. Bioconjug Chem. 2014 Nov 19;25(11):2012-20. doi: 10.1021/bc500392x. Epub 2014 Oct 22. PubMed PMID: 25291150; PubMed Central PMCID: PMC4240342. 10: Gao AX, Liao L, Johnson JA. Synthesis of Acid-Labile PEG and PEG-Doxorubicin-Conjugate Nanoparticles via Brush-First ROMP. ACS Macro Lett. 2014 Sep 16;3(9):854-857. Epub 2014 Aug 13. PubMed PMID: 25243099; PubMed Central PMCID: PMC4165536. 11: Li X, Takashima M, Yuba E, Harada A, Kono K. PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. Biomaterials. 2014 Aug;35(24):6576-84. doi: 10.1016/j.biomaterials.2014.04.043. Epub 2014 May 9. PubMed PMID: 24816361. 12: Zhang C, Pan D, Luo K, She W, Guo C, Yang Y, Gu Z. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Adv Healthc Mater. 2014 Aug;3(8):1299-308. doi: 10.1002/adhm.201300601. Epub 2014 Apr 6. PubMed PMID: 24706635. 13: Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials. 2014 May;35(14):4368-81. doi: 10.1016/j.biomaterials.2014.01.076. Epub 2014 Feb 22. PubMed PMID: 24565519. 14: Yang Y, Pan D, Luo K, Li L, Gu Z. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 2013 Nov;34(33):8430-43. doi: 10.1016/j.biomaterials.2013.07.037. Epub 2013 Jul 27. PubMed PMID: 23896006. 15: Sun CY, Dou S, Du JZ, Yang XZ, Li YP, Wang J. Doxorubicin conjugate of poly(ethylene glycol)-block-polyphosphoester for cancer therapy. Adv Healthc Mater. 2014 Feb;3(2):261-72. doi: 10.1002/adhm.201300091. Epub 2013 Jul 15. PubMed PMID: 23852934. 16: Wu DC, Cammarata CR, Park HJ, Rhodes BT, Ofner CM 3rd. Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate. Pharm Res. 2013 Aug;30(8):2087-96. doi: 10.1007/s11095-013-1065-9. Epub 2013 May 18. PubMed PMID: 23686374; PubMed Central PMCID: PMC3700642. 17: She W, Li N, Luo K, Guo C, Wang G, Geng Y, Gu Z. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013 Mar;34(9):2252-64. doi: 10.1016/j.biomaterials.2012.12.017. Epub 2013 Jan 5. PubMed PMID: 23298778. 18: Schoener CA, Carillo-Conde B, Hutson HN, Peppas NA. An inulin and doxorubicin conjugate for improving cancer therapy. J Drug Deliv Sci Technol. 2013;23(2):111-118. PubMed PMID: 24734120; PubMed Central PMCID: PMC3984582. 19: Ye WL, Teng ZH, Liu DZ, Cui H, Liu M, Cheng Y, Yang TH, Mei QB, Zhou SY. Synthesis of a new pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro. J Pharm Sci. 2013 Feb;102(2):530-40. doi: 10.1002/jps.23381. Epub 2012 Nov 20. PubMed PMID: 23169439. 20: Huan M, Cui H, Teng Z, Zhang B, Wang J, Liu X, Xia H, Zhou S, Mei Q. In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid. Biosci Biotechnol Biochem. 2012;76(8):1577-9. Epub 2012 Aug 7. PubMed PMID: 22878199.